Related Experiment Video

Updated: Jun 10, 2026

A Rat Orthotopic Renal Transplantation Model for Renal Allograft Rejection
06:59

A Rat Orthotopic Renal Transplantation Model for Renal Allograft Rejection

Published on: February 2, 2022

Insertion/Deletion polymorphism of Angiotensin-converting enzyme as a risk factor for chronic allograft nephropathy

R Fedor1, L Asztalos, L Löcsey

  • 1Department of Surgery, Transplantation Center, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary. f_roli@yahoo.com

Transplantation Proceedings
|August 10, 2010
PubMed

Insights

The angiotensin-converting enzyme (ACE) DD genotype is linked to chronic allograft nephropathy (CAN). This finding suggests ACE genotype may predict risk and guide ACE inhibitor therapy for kidney transplant patients.

Area of Science:

  • Nephrology
  • Genetics
  • Immunology

Background:

  • Chronic allograft nephropathy (CAN) treatment often involves angiotensin-converting enzyme (ACE) inhibitors, implying the renin-angiotensin system's role.
  • The specific role of ACE in CAN pathogenesis requires further elucidation.

Purpose of the Study:

  • To investigate the association between the ACE insertion/deletion polymorphism and the development of CAN.
  • To determine if ACE genotype influences serum ACE levels and activity in kidney transplant recipients.

Main Methods:

  • Analysis of ACE insertion/deletion polymorphism in kidney transplant recipients with CAN (n=38) and normal renal function (n=34).
  • Measurement of serum ACE concentration and activity in relation to ACE genotype.

Main Results:

  • The DD genotype was significantly more prevalent in the CAN group compared to the control group.
  • Individuals with the DD genotype exhibited higher serum ACE concentrations and activity than those with the II genotype.

Conclusions:

  • The ACE insertion/deletion polymorphism influences ACE expression and activity, potentially playing a role in CAN pathogenesis.
  • ACE genotype determination could aid in identifying patients at high risk for CAN.
  • The DD genotype may serve as an indicator for initiating ACE inhibitor therapy in kidney transplant recipients.

More Related Videos

Mouse Kidney Transplantation: Models of Allograft Rejection16:15

Mouse Kidney Transplantation: Models of Allograft Rejection

Published on: October 11, 2014

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...